Literature DB >> 31672920

Resolving the topological enigma in Ca2+ signaling by cyclic ADP-ribose and NAADP.

Hon Cheung Lee1, Yong Juan Zhao2.   

Abstract

Cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP) are two structurally distinct messengers that mobilize the endoplasmic and endolysosomal Ca2+ stores, respectively. Both are synthesized by the CD38 molecule (CD38), which has long been thought to be a type II membrane protein whose catalytic domain, intriguingly, faces to the outside of the cell. Accordingly, for more than 20 years, it has remained unresolved how CD38 can use cytosolic substrates such as NAD and NADP to produce messengers that target intracellular Ca2+ stores. The discovery of type III CD38, whose catalytic domain faces the cytosol, has now begun to clarify this topological conundrum. This article reviews the ideas and clues leading to the discovery of the type III CD38; highlights an innovative approach for uncovering its natural existence; and discusses the regulators of its activity, folding, and degradation. We also review the compartmentalization of cADPR and NAADP biogenesis. We further discuss the possible mechanisms that promote type III CD38 expression and appraise a proposal of a Ca2+-signaling mechanism based on substrate limitation and product translocation. The surprising finding of another enzyme that produces cADPR and NAADP, sterile α and TIR motif-containing 1 (SARM1), is described. SARM1 regulates axonal degeneration and has no sequence similarity with CD38 but can catalyze the same set of multireactions and has the same cytosolic orientation as the type III CD38. The intriguing finding that SARM1 is activated by nicotinamide mononucleotide to produce cADPR and NAADP suggests that it may function as a regulated Ca2+-signaling enzyme like CD38.
© 2019 Lee and Zhao.

Entities:  

Keywords:  CD38; SARM1; calcium intracellular release; calcium signaling; cyclic ADP ribose (cADPR); nicotinic acid adenine dinucleotide phosphate (NAADP); protein topology; signal transduction

Mesh:

Substances:

Year:  2019        PMID: 31672920      PMCID: PMC6937575          DOI: 10.1074/jbc.REV119.009635

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  92 in total

1.  A single residue at the active site of CD38 determines its NAD cyclizing and hydrolyzing activities.

Authors:  R Graeff; C Munshi; R Aarhus; M Johns; H C Lee
Journal:  J Biol Chem       Date:  2001-01-22       Impact factor: 5.157

2.  Connexin 43 hemi channels mediate Ca2+-regulated transmembrane NAD+ fluxes in intact cells.

Authors:  S Bruzzone; L Guida; E Zocchi; L Franco
Journal:  FASEB J       Date:  2000-11-09       Impact factor: 5.191

3.  A llama-derived gelsolin single-domain antibody blocks gelsolin-G-actin interaction.

Authors:  Anske Van den Abbeele; Sarah De Clercq; Ariane De Ganck; Veerle De Corte; Berlinda Van Loo; Sameh Hamdy Soror; Vasundara Srinivasan; Jan Steyaert; Joël Vandekerckhove; Jan Gettemans
Journal:  Cell Mol Life Sci       Date:  2010-02-07       Impact factor: 9.261

4.  The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration.

Authors:  Kow Essuman; Daniel W Summers; Yo Sasaki; Xianrong Mao; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Neuron       Date:  2017-03-22       Impact factor: 17.173

5.  Hippocampal mGluR1-dependent long-term potentiation requires NAADP-mediated acidic store Ca2+ signaling.

Authors:  William J Foster; Henry B C Taylor; Zahid Padamsey; Alexander F Jeans; Antony Galione; Nigel J Emptage
Journal:  Sci Signal       Date:  2018-11-27       Impact factor: 8.192

6.  Molecular basis for the transport of cytochrome P450 2E1 to the plasma membrane.

Authors:  E P Neve; M Ingelman-Sundberg
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

7.  Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels.

Authors:  Jun Liu; Yong Juan Zhao; Wan Hua Li; Yun Nan Hou; Ting Li; Zhi Ying Zhao; Cheng Fang; Song Lu Li; Hon Cheung Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-18       Impact factor: 11.205

8.  mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts.

Authors:  Ning Dai; Jan Christiansen; Finn C Nielsen; Joseph Avruch
Journal:  Genes Dev       Date:  2013-02-01       Impact factor: 11.361

9.  ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP.

Authors:  R Aarhus; R M Graeff; D M Dickey; T F Walseth; H C Lee
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

10.  ADP-ribosyl cyclase: an enzyme that cyclizes NAD+ into a calcium-mobilizing metabolite.

Authors:  H C Lee; R Aarhus
Journal:  Cell Regul       Date:  1991-03
View more
  21 in total

Review 1.  SARM1 can be a potential therapeutic target for spinal cord injury.

Authors:  Qicheng Lu; Benson O A Botchway; Yong Zhang; Tian Jin; Xuehong Liu
Journal:  Cell Mol Life Sci       Date:  2022-02-28       Impact factor: 9.261

Review 2.  CD38: A Potential Therapeutic Target in Cardiovascular Disease.

Authors:  Wanyun Zuo; Na Liu; Yunhong Zeng; Yaozhong Liu; Biao Li; Keke Wu; Yunbin Xiao; Qiming Liu
Journal:  Cardiovasc Drugs Ther       Date:  2021-08       Impact factor: 3.727

Review 3.  CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity.

Authors:  Zayda L Piedra-Quintero; Zachary Wilson; Porfirio Nava; Mireia Guerau-de-Arellano
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

Review 4.  Enzymology of extracellular NAD metabolism.

Authors:  Massimiliano Gasparrini; Leonardo Sorci; Nadia Raffaelli
Journal:  Cell Mol Life Sci       Date:  2021-03-23       Impact factor: 9.261

Review 5.  Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.

Authors:  Beatrice Anna Zannetti; Angelo Corso Faini; Evita Massari; Massimo Geuna; Enrico Maffini; Giovanni Poletti; Claudio Cerchione; Giovanni Martinelli; Fabio Malavasi; Francesco Lanza
Journal:  Cells       Date:  2020-12-11       Impact factor: 6.600

Review 6.  CD38, CD157, and RAGE as Molecular Determinants for Social Behavior.

Authors:  Haruhiro Higashida; Minako Hashii; Yukie Tanaka; Shigeru Matsukawa; Yoshihiro Higuchi; Ryosuke Gabata; Makoto Tsubomoto; Noriko Seishima; Mitsuyo Teramachi; Taiki Kamijima; Tsuyoshi Hattori; Osamu Hori; Chiharu Tsuji; Stanislav M Cherepanov; Anna A Shabalova; Maria Gerasimenko; Kana Minami; Shigeru Yokoyama; Sei-Ichi Munesue; Ai Harashima; Yasuhiko Yamamoto; Alla B Salmina; Olga Lopatina
Journal:  Cells       Date:  2019-12-25       Impact factor: 6.600

Review 7.  The Circular Life of Human CD38: From Basic Science to Clinics and Back.

Authors:  Alberto L Horenstein; Angelo C Faini; Fabio Morandi; Cristiano Bracci; Francesco Lanza; Nicola Giuliani; Aneel Paulus; Fabio Malavasi
Journal:  Molecules       Date:  2020-10-21       Impact factor: 4.411

8.  Neurodegeneration Caused by S1P-Lyase Deficiency Involves Calcium-Dependent Tau Pathology and Abnormal Histone Acetylation.

Authors:  Shah Alam; Antonia Piazzesi; Mariam Abd El Fatah; Maren Raucamp; Gerhild van Echten-Deckert
Journal:  Cells       Date:  2020-09-28       Impact factor: 6.600

Review 9.  NAD+ metabolism, stemness, the immune response, and cancer.

Authors:  Lola E Navas; Amancio Carnero
Journal:  Signal Transduct Target Ther       Date:  2021-01-01

Review 10.  CD38 in the age of COVID-19: a medical perspective.

Authors:  Alberto L Horenstein; Angelo C Faini; Fabio Malavasi
Journal:  Physiol Rev       Date:  2021-03-31       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.